查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1593035

静脉注射免疫球蛋白市场：按适应症、剂型和最终用户分类 - 全球预测 2025-2030

Intravenous Immunoglobulin Market by Indication (Primary Immunodeficiency, Secondary Immunodeficiency), Form (Liquid IVIG, Lyophilized IVIG), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年静脉注射免疫球蛋白市场价值为12.5亿美元，预计到2024年将达到13.3亿美元，复合年增长率为6.92%，到2030年将达到19.9亿美元。

静脉注射免疫球蛋白 (IVIG) 疗法涉及向患者施用抗体组合，主要用于治疗多种免疫力缺乏和自体免疫疾病。 IVIG在原发性免疫力缺乏、慢性脱髓鞘多发性神经炎、甚至某些神经系统疾病的治疗中的需求和应用凸显。最终用途范围从医院和诊所到居家医疗，凸显了其多功能的医疗应用。 IVIG 市场主要是由自体免疫疾病盛行率上升以及通常更容易受到此类疾病影响的老年人口不断增加所推动的。此外，製造技术的进步和免疫球蛋白治疗意识的提高也推动了市场的成长。该市场的最新机会集中在开拓国家，这些国家的医疗基础设施有所改善，生物製药研究投资增加。利用这些机会的建议包括探索与医疗保健提供者的策略联盟和伙伴关係，以及加强分销网络以确保广泛的产品覆盖范围。然而，市场面临高昂的治疗成本、严格的法律规范以及与 IVIG 治疗相关的潜在副作用（例如过敏反应）等限制。漫长而复杂的製造流程所导致的供应限制也带来了挑战。在技​​术创新方面，个人化医疗和新配方开发等领域具有显着的业务成长潜力。此外，探索替代的递送方法，例如皮下免疫球蛋白，也可能提供竞争优势。 IVIG 市场竞争激烈且研究密集型，其特点是持续的产品开发和严格遵守监管标准。因此，有效地将扎实的研究、策略伙伴关係和深思熟虑的市场扩张结合起来的公司可能会在这个不断变化的环境中取得成功。

主要市场统计
基准年[2023] 12.5亿美元
预测年份 [2024] 13.3亿美元
预测年份 [2030] 19.9亿美元
复合年增长率（%） 6.92%

市场动态：快速发展的静脉免疫球蛋白市场的关键市场静脉注射

供需的动态交互作用正在改变静脉注射免疫球蛋白市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 慢性脱髓鞘多发性神经炎(CIDP) 和低丙种球蛋白血症的盛行率迅速增加
    • 老年人口和血友病患者显着增加
    • 静脉注射免疫球蛋白产品的仿单标示外使用增加
  • 市场限制因素
    • 政府对静脉注射免疫球蛋白产品的使用有严格的规定
  • 市场机会
    • 免疫球蛋白生产改良技术的出现
    • 静脉注射免疫球蛋白产品核准数量不断增加
  • 市场挑战
    • 静脉注射免疫球蛋白产品相关副作用的高风险

波特五力：驾驭静脉注射免疫球蛋白市场的策略工具

波特的五力框架是了解静脉注射免疫球蛋白市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对静脉注射免疫球蛋白市场的影响

外部宏观环境因素在塑造静脉注射免疫球蛋白市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解静脉注射免疫球蛋白市场的竞争状况

静脉注射免疫球蛋白市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵静脉注射免疫球蛋白市场供应商的绩效评估

FPNV定位矩阵是评估静脉注射市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划静脉注射免疫球蛋白市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，静脉注射免疫球蛋白市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性脱髓鞘多发性神经炎(CIDP) 和低丙种球蛋白血症的盛行率迅速增加
      • 老年人口和血友病患者显着增加
      • 静脉注射免疫球蛋白产品中仿单标示外适应症的使用增加
    • 抑制因素
      • 政府对静脉注射免疫球蛋白产品的使用有严格的规定
    • 机会
      • 免疫球蛋白生产改良技术的出现
      • 静脉注射免疫球蛋白产品核可数量增加
    • 任务
      • 静脉注射免疫球蛋白产品相关副作用的高风险
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章静脉注射免疫球蛋白市场依适应症分类

  • 原发性免疫力缺乏
  • 继发性免疫力缺乏缺陷

第七章静脉注射免疫球蛋白市场：依形式

  • 液体IVIG
  • 冻干IVIG

第八章静脉注射免疫球蛋白市场：依最终使用者分类

  • 居家照护设施
  • 医院/诊所

第九章北美及南美静脉注射免疫球蛋白市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太静脉注射免疫球蛋白市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲静脉注射免疫球蛋白市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • ADMA Biologics, Inc.
  • Baxter International, Inc.
  • Bayer HealthCare LLC
  • Biotest AG by Grifols SA
  • CSL Behring
  • Johnson & Johnson Services, Inc.
  • Kedrion SpA
  • LFB Biotechnologies
  • Octapharma AG
  • Option Care Health, Inc.
Product Code: MRR-FF012EDC38B0

The Intravenous Immunoglobulin Market was valued at USD 1.25 billion in 2023, expected to reach USD 1.33 billion in 2024, and is projected to grow at a CAGR of 6.92%, to USD 1.99 billion by 2030.

Intravenous Immunoglobulin (IVIG) therapy involves administering a mixture of antibodies to patients, primarily used for treating a myriad of immune deficiencies and autoimmune diseases. The necessity and application of IVIG are underscored in the treatment of conditions such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and even in certain neurological disorders. The end-use scope ranges from hospitals and clinics to homecare settings, highlighting its versatile medical application. The market for IVIG is primarily driven by the rising prevalence of autoimmune disorders and a growing geriatric population, which generally presents a higher susceptibility to such medical conditions. Additionally, advancements in production technology and increasing awareness about immunoglobulin therapies foster market growth. The latest opportunities within the market are centered around untapped emerging economies with improving healthcare infrastructure and increasing investment in biopharmaceutical research. Recommendations to capitalize on these opportunities include exploring strategic alliances and partnerships with healthcare providers and enhancing the distribution network to ensure wider product reach. However, the market faces limitations such as high treatment costs, stringent regulatory frameworks, and potential side effects associated with IVIG therapies, such as allergic reactions. Challenges also emerge from supply constraints due to the lengthy and complex production process. In terms of innovation, areas such as personalized medicine and new formulation developments hold potential for substantial business growth. Additionally, research into alternative delivery methods, like subcutaneous immunoglobulin, could provide a competitive edge. The nature of the IVIG market is highly competitive and research-intensive, characterized by continuous product development and strict adherence to regulatory standards. Consequently, companies that effectively combine robust research, strategic partnerships, and thoughtful market expansions are likely to thrive in the evolving landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 1.25 billion
Estimated Year [2024] USD 1.33 billion
Forecast Year [2030] USD 1.99 billion
CAGR (%) 6.92%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Intravenous Immunoglobulin Market

The Intravenous Immunoglobulin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Surge in the prevalence of chronic inflammatory demyelinating polyneuropathy (CIDP) and hypogammaglobulinemia
    • Significant rise in geriatric population and number of hemophilic patients
    • Rising use of off-label indications in intravenous immunoglobulin products
  • Market Restraints
    • Stringent government regulations toward the use of intravenous immunoglobulin products
  • Market Opportunities
    • Emergence of improved technologies in immunoglobulin production
    • Increasing number of intravenous immunoglobulin product approvals
  • Market Challenges
    • High risk of side effects associated with intravenous immunoglobulin products

Porter's Five Forces: A Strategic Tool for Navigating the Intravenous Immunoglobulin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Intravenous Immunoglobulin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Intravenous Immunoglobulin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Intravenous Immunoglobulin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Intravenous Immunoglobulin Market

A detailed market share analysis in the Intravenous Immunoglobulin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Intravenous Immunoglobulin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Intravenous Immunoglobulin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Intravenous Immunoglobulin Market

A strategic analysis of the Intravenous Immunoglobulin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Intravenous Immunoglobulin Market, highlighting leading vendors and their innovative profiles. These include ADMA Biologics, Inc., Baxter International, Inc., Bayer HealthCare LLC, Biotest AG by Grifols S.A., CSL Behring, Johnson & Johnson Services, Inc., Kedrion S.p.A., LFB Biotechnologies, Octapharma AG, and Option Care Health, Inc..

Market Segmentation & Coverage

This research report categorizes the Intravenous Immunoglobulin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Primary Immunodeficiency and Secondary Immunodeficiency.
  • Based on Form, market is studied across Liquid IVIG and Lyophilized IVIG.
  • Based on End-User, market is studied across Homecare Facilities and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surge in the prevalence of chronic inflammatory demyelinating polyneuropathy (CIDP) and hypogammaglobulinemia
      • 5.1.1.2. Significant rise in geriatric population and number of hemophilic patients
      • 5.1.1.3. Rising use of off-label indications in intravenous immunoglobulin products
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent government regulations toward the use of intravenous immunoglobulin products
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of improved technologies in immunoglobulin production
      • 5.1.3.2. Increasing number of intravenous immunoglobulin product approvals
    • 5.1.4. Challenges
      • 5.1.4.1. High risk of side effects associated with intravenous immunoglobulin products
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Intravenous Immunoglobulin Market, by Indication

  • 6.1. Introduction
  • 6.2. Primary Immunodeficiency
  • 6.3. Secondary Immunodeficiency

7. Intravenous Immunoglobulin Market, by Form

  • 7.1. Introduction
  • 7.2. Liquid IVIG
  • 7.3. Lyophilized IVIG

8. Intravenous Immunoglobulin Market, by End-User

  • 8.1. Introduction
  • 8.2. Homecare Facilities
  • 8.3. Hospitals & Clinics

9. Americas Intravenous Immunoglobulin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Intravenous Immunoglobulin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Intravenous Immunoglobulin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ADMA Biologics, Inc.
  • 2. Baxter International, Inc.
  • 3. Bayer HealthCare LLC
  • 4. Biotest AG by Grifols S.A.
  • 5. CSL Behring
  • 6. Johnson & Johnson Services, Inc.
  • 7. Kedrion S.p.A.
  • 8. LFB Biotechnologies
  • 9. Octapharma AG
  • 10. Option Care Health, Inc.

LIST OF FIGURES

  • FIGURE 1. INTRAVENOUS IMMUNOGLOBULIN MARKET RESEARCH PROCESS
  • FIGURE 2. INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. INTRAVENOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. INTRAVENOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INTRAVENOUS IMMUNOGLOBULIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INTRAVENOUS IMMUNOGLOBULIN MARKET DYNAMICS
  • TABLE 7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID IVIG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED IVIG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOMECARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. INTRAVENOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 144. INTRAVENOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2023